Issue 35

What can CDMOs do to Successfully Ride the Oral GLP-1 Wave?

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Riding the Oral GLP-1 Wave

Glucagon-like peptide-1 (GLP-1) receptor agonists first penetrated the market 20 years ago when exenatide (Byetta, originally developed by Amylin Pharmaceuticals and Eli Lilly) gained regulatory approval as a novel treatment option for type 2 diabetes. Since that time, there have been approvals for multiple GLP-1s indicated for the treatment of diabetes and a few, over the course of the past decade, indicated for weight loss.

Read more here.

FEATURED STORIES

Amgen Further Commits to U.S. Manufacturing with Ohio Investment

Read more here.

PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition

Read more here.

Granite Bio Emerges from Stealth to Advance Immunology Pipeline

Read more here.

Roche Commits Billions to Strengthening U.S. Presence

Read more here.

GemPharmatech Advances Expansion Strategy with New Facility in San Diego

Read more here.

Syntegon Launches New Filling Machine for RTU Syringes

Read more here.

FDA Approves AbbVie’s JAK Inhibitor Therapy to Treat GCA

Read more here.

Merck Enters Definitive Agreement to Acquire SpringWorks Therapeutics

Read more here.